GCM
INBX

Graham Capital Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Graham Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,135
Closed -$203K – 1331
2022
Q1 		$203K Buy
+9,135
New +$233K 0.01% 826

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Graham Capital Management's INBX Position: Q2 2022 in Review

Graham Capital Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2022, closing a stake of 9,135 shares — an estimated $203K sold.

Graham Capital Management first reported a position in INBX in Q1 2022 and held it in 1 quarter. The position peaked at $203K in Q1 2022. 100 funds tracked by Wall St. Rank hold INBX as of Q2 2022.

  • Graham Capital Management reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Graham Capital Management sold 9,135 Inhibrx, Inc. Common Stock shares in Q2 2022, an estimated $203K.
  • Graham Capital Management first reported a position in Inhibrx, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Graham Capital Management's Inhibrx, Inc. Common Stock position peaked at $203K in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2022.

Based on Graham Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.